{"filing":{"accession_number":"0001213900-26-079674","cik":"0001837821","ticker":"ZJYL","company_name":"Jin Medical International Ltd.","form":"6-K","filing_date":"2026-07-20","report_date":null,"primary_document":"ea0298591-6k_jinmedical.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1837821/000121390026079674/ea0298591-6k_jinmedical.htm"},"events":[{"id":18857,"run_id":16961,"accession_number":"0001213900-26-079674","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This 6-K discloses the results of shareholder votes held on July 20, 2026, including three separate meetings (Class A, Class B, and Extraordinary General Meeting). The disclosure reports voting results on material matters including: (1) increase of voting rights for Class B shares from 30 to 800 votes; (2) repurchase of 3.77 million Class A shares held by the CEO's entity; (3) issuance of 3.77 million Class B shares to the CEO's entity; (4) increase in authorized share capital; (5) adoption of amended articles of association; and (6) approval of a VIE acquisition of Beijing Tongsheng Technology with issuance of 64.2 million Class A shares as consideration. These are material governance and capital structure changes requiring shareholder approval.","company_name":"Jin Medical International Ltd.","ticker":"ZJYL","filing_date":"2026-07-20","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":17796,"accession_number":"0001213900-26-079674","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This 6-K discloses the results of shareholder votes held on July 20, 2026, including three separate meetings (Class A, Class B, and Extraordinary General Meeting). The disclosure reports voting results on material matters including: (1) increase of voting rights for Class B shares from 30 to 800 votes; (2) repurchase of 3.77 million Class A shares held by the CEO's entity; (3) issuance of 3.77 million Class B shares to the CEO's entity; (4) increase in authorized share capital; (5) adoption of amended articles of association; and (6) approval of a VIE acquisition of Beijing Tongsheng Technology with issuance of 64.2 million Class A shares as consideration. These are material governance and capital structure changes requiring shareholder approval.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-20T20:56:37.365498+00:00","company_name":"Jin Medical International Ltd.","ticker":"ZJYL","filing_date":"2026-07-20"}]}